Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02318784 · ClinicalTrials.gov registry record · Phase 2
Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT02318784 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 62 participants.
The verdict
NCT02318784, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if carfilzomib is safe and effective in the treatment of patients with advanced neuroendocrine tumors.
Interventions
- DRUG Carfilzomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2015-07-15 |
| Est. Completion | 2021-05-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02318784
The ClinicalTrials.gov registry entry for NCT02318784 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Carfilzomib is the first listed.
NCT02318784 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02318784 about?
NCT02318784 is a clinical study titled "Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers". The purpose of this study is to determine if carfilzomib is safe and effective in the treatment of patients with advanced neuroendocrine tumors.
What is the current status of trial NCT02318784?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2015-07-15. Estimated completion is 2021-05-15.
What interventions are being tested in trial NCT02318784?
The interventions under investigation include: Carfilzomib (DRUG).
Who is sponsoring clinical trial NCT02318784?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.